Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, May 11 2016

Full Issue

Opposition Fierce For Medicare Plan To Cut Pay For Drugs As Comment Period Ends

The plan, which affects drugs such as cancer treatments given in outpatient settings, has drawn more than 1,300 comments.

Modern Healthcare: Tension Mounts Over Medicare's Bid To Remove Profit Motive From Outpatient Drugs

The comment period closed this week on the Obama administration's bold proposal to rewire how Medicare pays for outpatient drugs, and the CMS is under intense pressure to scrap it. Providers across the board, not just those projected to receive the deepest cuts under the proposal, have misgivings about the initiative. That's because it's hard to truly know the implications until its second phase kicks in, said Thomas Barker, an attorney and co-chair of the health practice at Foley Hoag. “There is skepticism about CMS's projections because it's too soon to see how this will shake out,” said Barker, former acting general counsel at HHS. (Dickson, 5/10)

For more drug pricing news, check out our weekly feature, Prescription Drug Watch, which includes coverage and perspectives of the issue.

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, July 16
  • Wednesday, July 15
  • Tuesday, July 14
  • Monday, July 13
  • Friday, July 10
  • Thursday, July 9
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF